Patent SG-11201909495P-A (SG)
Title: Combination cancer immunotherapy with pentaaza macrocyclic ring complex
Inventor: BEARDSLEY ROBERT A
IPC: A61K33/32
Filed: 2018-04-13
Abstract: wI) ---G:GC4419(1)1anti-PD1 RMP1-1415 ---4---GIGC4419(10) G5:GC4419(3)lanii-PD1 RMP1 1415 RMP1-14(5) —13--MGC4419(10)/anti-PD1 RMP -1 5) 1500 20 40 Days Post Tumor Implantation FIG. 1 W O 20 18/ 19 167 6 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I PO I PCT omit VIII °nolo mu Oil 1001111 IIII iflo oimIE (10) International Publication Number WO 2018/191676 Al (51) International Patent Classification: A61K 33/32 (2006.01) A61K 39/395 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/027588 (22) International Filing Date: 13 April 2018 (13.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/485,061 13 April 2017 (13.04.2017) US 62/572,377 13 October 2017 (13.10.2017) US (71) Applicant: GALERA LABS, LLC [US/US]; 1100 Corpo- rate Square Drive, Suite 223, Creve Coeur, Missouri 63132 (US). (72) Inventors: BEARDSLEY, Robert A.; 6935 Waterman Ave, University City, Missouri 63130 (US). KEENE, Jef- fery L.; 8100 Leafland Court, St. Louis, Missouri 63123 (US). RILEY, Dennia P.; 1722 Claymont Estates Drive, Chesterfield, Missouri 63107 (US). (74) Agent: COTTON, Abigail; c/o Bryan Cave LLP, 211 North Broadway, Suite 3600, St. Louis, Missouri 63102 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX (57) : A method of treating a cancer in a mammalian sub- ject afflicted with the cancer, includes administering to the subject an immune checkpoint inhibitor, and administering to the subject a pentaaza macrocyclic ring complex corresponding to the formula (I) below, prior to, concomitantly with, or after administration of the immune checkpoint inhibitor, to increase the response of the cancer to the immune checkpoint inhibitor. [Continued on next page] WO 2018/191676 Al D ill Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))